Diagnosis of and therapy for non-muscle-invasive bladder cancer state of the art;Diagnostik und Therapie des nicht muskelinvasiven Harnblasenkarzinoms State of the Art

Aktuelle Urologie

Volumn 41, Issue 5, 2010, Pages 307-315

  Kausch Von Schmeling, I ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

bladder cancer; diagnosis; instillation; markers; therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ARTICLE; BLADDER; BLADDER TUMOR; CANCER INVASION; CANCER STAGING; CYSTECTOMY; CYSTOSCOPY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; CYSTOSCOPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 77956587079     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0030-1262555     Document Type: Article

References (77)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009 CA. Cancer J Clin 2009 59 225-249
2. http://www.rki.de.
3. Sylvester R J., van der Meijden A P., Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596patients from seven EORTC trials. Eur Urol 2006 49 466-475
4. Burger M, van der Aa M NM, van Oers J MM et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008 54 835-844
5. Williams S G., Stein J P. Molecular pathways in bladder cancer. Urol Res 2004 32 373-385
6. Wolff E M., Liang G, Jones P A. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005 2 502-510
7. Knowles M A. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008 13 287-297
8. Goessl C, Knispel H H., Miller K et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 1997 157 480-481
9. Holmang S, Hedelin H, Anderstrom C et al. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol 1998 160 45-48
10. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 66 4-34
11. Oosterlinck W, Solsona E, Akaza H et al. Low-grade Ta urothelial carcinoma of the bladder. Urology 2005 66 75-89
12. Sauter G, Algaba F, Amin M et al. Non-invasive urothelial neoplasias. WHO classification of non-invasive papillary urothelial tumors. In: EbleJN, SauterG, EpsteinJI, SesterhennI, eds. World Health Organization classification of tumors. Pathology and genetics: Tumors of the urinary system and male genital organs. Lyon: IARCC Press; 2004: 89157
13. Jichlinski P, Leisinger H J. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int 2005 74 97-101
14. Burger M, Stief C G., Zaak D et al. Hexaminolaevulinate is equal to 5-Aminolaevilinic Acid concerning residual tumour and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumours. Urology 2009 74 1282-1286
15. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008 54 303-314
16. Kausch I, Sommerauer M, Montorsi F et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2009 (epub ahead of print)
17. Herr H W., Donat S M. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008 102 1111-1114
18. Bryan R T., Billingham L J., Wallace D M. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int 2008 101 702-705
19. Cauberg E C., Kloen S, Visser M et al. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology 2010 (Epub ahead of print)
20. Karakiewicz P I., Benayoun S, Zippe C et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006 97 997-1001
21. Kausch I, Böhle A. Bladder cancer. II.Molecular aspects and diagnosis. Eur Urol 2001 39 498-506
22. Van Rhijn B W., van der Poel H G., van der Kwast T H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005 47 736-748
23. Shariat S F., Karam J A., Lotan Y et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Reviews in Urol 2008 10 120-135
24. Lotan Y, Svatek R S., Sagalowsky A I. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer 2006 107 982-990
25. Vriesema J L., Poucki M H., Kiemeney L A. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 2000 56 793-797
26. Habuchi T, Marberger M, Droller M J. et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 2005 66 64-74 (Pubitemid 43049609)
27. Bryan R T., Zeegers M P., James N D. et al. Biomarkers in bladder cancer. BJU Int 2009 105 608-613
28. Karam J A., Lotan Y, Karakiewicz P l et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncology 2007 8 128-136
29. Margulis V, Shariat S F., Ashfaq R et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006 12 7369-7373
30. Margulis V, Lotan Y, Karakiewicz P I. et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. JNCI 2009 101 114-119
31. Shariat S F., Svatek R S., Tilki D et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010 105 1402-1412
32. Riley R D., Sauerbrei W, Altman D G. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009 100 1219-1229
33. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000 164 680-684
34. Sylvester R J., van der Meijden A PM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596patients from seven EORTC trials. Eur Urol 2006 49 466-477
35. Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008 53 992-1001
36. Fernandez-Gomez J, Madero R, Solsona E et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients with bacillus Calmette-Guerin:the CUETO scoring model. J Urol 2009 182 2195-2203
37. Sylvester R J., Oosterlinck W, van der Meijden A P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004 171 2186-2190
38. Bouffioux C, Kurth K H., Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2European Organization for Research and Treatment of Cancer randomized trials with mitomycinC and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995 153 934-941
39. Berrum-Svennung I, Granfors T, Jahnson S et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008 179 101-105
40. Gudjonson S, Adell L, Merdasa F et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomized multicentre study. Eur Urol 2009 55 773-780
41. Cai T, Nesi G, Tinacci G et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008 180 110-115
42. Hendricksen K, Witjes W P., Idema J G. et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 2008 53 984-991
43. Sylvester R J., Oosterlinck W. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Has the evidence changed? Eur Urol 2009 56 43-45
44. Sylvester R J., Oosterlinck W, Witjes J A. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008 53 709-719
45. Au J L., Badalament R A., Wientjes M G. et al. Methods to improve efficacy of intravesical mitomycinC: results of a randomized phaseIII trial. JNCI 2001 93 597-604
46. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003 170 964-969
47. Martinez-Pineiro J A., Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Cis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005 174 1242-1247
48. Colombel M, Saint F, Chopin D et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006 176 935-939
49. Shelley M D., Mason M D., Kynaston H. Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. Cancer Treatment Rev 2010 36 195-205
50. de Reijke T M., Kurth K H., Sylvester R J., et al., European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group PhaseIII Trial (30906). J Urol 2005 173 405-409
51. Järvinen R, Kaasinen E, Sankila A et al. Long-term efficacy of maintenance bacillus Calmette Guerin versus maintenance mitomycinc instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009 56 260-265
52. Sylvester R J., van der Meijden A P., Lamm D L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002 168 1964-1970
53. Böhle A, Bock P R. Intravesical bacillus Calmette-Guerin versus mitomycinC in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004 63 682-687
54. Pawinski A, Sylvester R, Kurth K H. et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of Ta T1 bladder cancer. EORTC Cooperative group and the Medical Research Council Working Party on superficial bladder cancer. JUrol 1996 156 1934-1941
55. Malmström P -U, Sylvester R J., Crawford D E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycinc versus bacillus Calmette Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009 56 247-256
56. Hendricksen K, van der Heijden A G., Cornel E B. et al. Two-year follow-up of the phaseII marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 2009 176 337-342
57. Böhle A, Leyh H, Frei C et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phaseIII multicentre study. S274 Study Group. Eur Urol 2009 56 495-503
58. Porena M, Del Zingaro M, Lazzeri M et al. Bacillus Calmette-Gurin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 2010 84 23-27
59. Addeo R, Caraglia M, Bellini S et al. Randomized phaseIII trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010 28 543-548
60. Di Lorenzo G, Perdon S, Damiano R et al. Gemcitabine versus bacille Calmette-Gurin after initial bacille Calmette-Gurin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010 116 1893-1900
61. Joudi F N., Smith B J., O'Donnell M A. Final results from a national multicenter phaseII trial of combination bacillus Calmette-Guerin plus interferon alpha-B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006 24 344-348
62. Lingnau A, Steiner U, Kurzidim H et al. PhaseI dose-escalation study of intravesical instillation of antisense oligonucleotide FFC15-01 against Ki-67 in patients with superficial bladder cancer. Debates on bladder cancer 2010 2 1-6
63. Jocham D, Windeler J, Jensen K et al. BCG versus Photodynamische Therapie (PDT) beim nicht muskelinvasiven Harnblasenkarzinom eine multizentrische Phase-III-Studie. Akt Urol 2009 40 91-99
64. van der Heijden A G., Kiemeney L A., Gofrit O N. et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004 46 65-71
65. Colombo R, Da Pozzo L F., Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003 21 4270-4276
66. Witjes A, Hendricksen K, Gofrit O et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European synergo working party. World J Urol 2009 27 319-324
67. Di Stasi S M., Gianpantoni A, Stephen R L. et al. Intravesical electromotive mitomycinC versus passive transport mitomycinC for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003 170 777-782
68. Di Stasi S M., Storti L, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol 2006 7 43-51
69. Di Stasi S M., Storti L, Giurioli A. Single immediate preoperative instillation of electromotive mitomycin-C plus transurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C fot pTa bladder tumors: long-term results of a prospective randomized trial. J Urol 2008 179 (S4) 585-585
70. Lamm D, Colombel M, Persad R et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008 7 651-666
71. Schrier B P., Hollander M P., van Rhijn B W. et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004 45 292-296
72. Guzzo T J., Magheli A, Bivalacqua T J. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology 2009 74 1276-1280
73. Nieder A M., Brausi M, Lamm D et al. Management of stage T1 tumors ofthe bladder: international consensus panel. Urology 2005 66 (6Suppl1) 108-125
74. Fritsche H M., Burger M, Svatek R S. et al. Characteristics and outcomes ofpatients with clinical T1 grade3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010 57 300-309
75. Denzinger S, Burger M, Fritsche H M. et al. Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making? Akt Urol 2008 39 58-61
76. Denzinger S, Fritsche H M., Otto W et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2007 53 146-152
77. Stanislaus P, Zaak D, Stadler T et al. Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. World J Urol 2010 28 407-411